Mylan Discontinues, Transfers Products In Wake of FDA Warning Letter
Posted 21 November 2018 | By
A recently issued US Food and Drug Administration (FDA) warning letter escalated previously observed issues around quality control at Mylan Pharmaceuticals’ manufacturing facility in Morgantown, WV, to significant violations of good manufacturing practices (GMP).
The warning letter posted on Tuesday took issue with the firm’s May response to the 13 inspectional citations outlined
in a Form 483, following an inspection conducted by FDA investigators between March and April. Mylan was quick to issue a response to the warning.
“Mylan has proactively discontinued a number of products from the site while also transferring some products to other sites. These actions have led to a temporary disruption in supply of certain Mylan products for customers,” the firm said on Tuesday, adding that the latest warning letter to its Morgantown plant is “the sole outstanding FDA warning letter to Mylan.”
The new enforcement action comes at a time when regulatory authorities across several countries are grappling with a shortage of Mylan’s EpiPen. Pfizer and Mylan also reported
earlier this month a labeling defect on EpiPen 0.3 mg and EpiPen Jr 0.15 mg formats could prevent the autoinjectors from administering epinephrine.
The Morgantown warning letter cites three specific GMP violations, including inadequacies in the firm’s validation and verification program, out-of-specification (OOS) results and observed process deviations.
FDA also dinged the company’s site for an insufficient cleaning program and a lack of an “adequate ongoing program for monitoring process control to ensure stable manufacturing operations and consistent drug quality.” A repeat GMP violation is “the unjustified invalidation of failing test results.”
The agency also found the firm’s response insufficient in that it lacked evidence in support of a validated cleaning program and a comprehensive retrospective evaluation of all investigations for implementation of an appropriate corrective and preventive action (CAPA) plan. The firm’s facility “lack of rigorous oversight of manufacturing changes continues to be a major factor in the unexpected variation observed in your drug products,” according to the agency investigators.
Mylan’s facility had yet to complete several of its commitments regarding initiated CAPAs at the time of its response to the 483, despite set 2017 due dates, as previously reported
The warning letter noted FDA cited similar violations across three Mylan facilities and Mylan Laboratories since 2015. “These repeated failures at multiple sites demonstrate that Mylan’s management oversight and control over the manufacture of drugs is inadequate,” FDA said.
A 2017 FDA warning letter to an India-based Mylan facility identified
a repeat observation from 2015 regarding unidentified trends in OOS investigations. “We continuously learn from inspections of our facilities by FDA and other authorities as regulatory expectations continue to evolve,” the firm added in its Tuesday response. “In 2018, global health authorities conducted more than 100 regulatory inspections, including 21 FDA inspections, of our nearly 50 other manufacturing facilities around the world without regulatory action or significant observations.”
Ronny Gal, a senior analyst at Bernstein Research, discussed his thoughts on the latest warning letter to Mylan in a new report. He argued it will be challenging for Mylan to lift the letter.
“The saving grace is that there is no immediate impact to near term high value launches,” Gal said. “The biosimilars, Advair, and we believe Restasis do not come from Morgantown.” He also suggested a shutdown of the Morgantown facility based on a “systemic risk for the company,” the unlikelihood that the facility is “currently above marginal profitability” over costs associated with remediation and the US remaining the “higher cost manufacturing site in the global system.”
Mylan Pharmaceuticals Inc. 11/9/18